×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Americas Gastrointestinal Drugs Market Share

ID: MRFR/Pharma/0140-HCR
50 Pages
Kinjoll Dey
October 2025

Americas Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs, and Others), By Route of Administration (Oral, Parenteral, Rectal), By disease type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other), By end user (Hospital Pharmacies, Retail Pharmacies and Other) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Americas Gastrointestinal Drugs Market Infographic
Purchase Options

Market Share

Americas Gastrointestinal Drugs Market Share Analysis

The Americas Gastrointestinal Drug market, a basic domain inside the drug business, requires nuanced methodologies to address the different scope of gastrointestinal issues predominant across the locale. Effectively situating inside this powerful market demands a far-reaching way to deal with take care of the one-of-a-kind requirements of patients and healthcare experts. Improving market share includes disease-explicit drug improvement. Tailoring drugs for conditions like irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), or inflammatory bowel disease (IBD) permits organizations to address the unmistakable necessities of patients, encouraging designated therapeutic approaches. It is significant to pioneering advancements in treatment modalities. Organizations should put resources into innovative work to present novel drug plans, delivery techniques, and components of activity. Advancements that further develop viability, lessen results, or upgrade patient adherence can essentially influence market share. Expanding market presence universally while considering territorial varieties in gastrointestinal health rehearses is essential. Understanding the assorted patient populations and healthcare frameworks across various nations in the Americas permits organizations to tailor their drug systems successfully, adding to expanded market share. Creating financially smart drugs without compromising quality is an essential methodology. Offering patient help programs, limited valuing, or conventional options requests to healthcare suppliers and patients looking for reasonable answers for gastrointestinal conditions, reinforcing market share. Focusing on a patient-centric methodology in drug improvement can separate organizations. Arrangements that emphasis on working on patient comfort, limiting treatment trouble, and upgrading long haul results resound well with both healthcare experts and patients, adding to improved market share. Cautiously checking contender exercises and remaining informed about market patterns is basic. Organizations that adjust their procedures considering contender developments can remain significant and line up with advancing market demands really. Laying out vigorous post-market observation systems and effectively looking for client criticism add to progressing item improvement. Organizations that utilization genuine information and patient encounters to upgrade their gastrointestinal drugs show a devotion to constant improvement and consumer loyalty.

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Leave a Comment

Market Summary

The United States of America gastrointestinal drugs market is projected to grow from 12.3 USD billion in 2024 to 19.7 USD billion by 2035.

Key Market Trends & Highlights

Americas Gastrointestinal Drugs Market Key Trends and Highlights

  • The market is expected to experience a compound annual growth rate of 4.34 percent from 2025 to 2035.
  • By 2035, the gastrointestinal drugs market in the United States is anticipated to reach a valuation of 19.7 USD billion.
  • In 2024, the market is valued at 12.3 USD billion, indicating a robust growth trajectory.
  • Growing adoption of innovative treatment options due to increasing prevalence of gastrointestinal disorders is a major market driver.

Market Size & Forecast

2024 Market Size 12.3 (USD Billion)
2035 Market Size 19.7 (USD Billion)
CAGR (2025-2035) 4.34%
Largest Regional Market Share in 2024 latin_america)

Major Players

AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories (US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany), Evoke Pharma (US), Valent Pharmaceuticals (US)

Market Trends

Americas Gastrointestinal Drugs Market Market Drivers

Market Segment Insights

Regional Insights

Key Companies in the Americas Gastrointestinal Drugs Market market include

Industry Developments

Market Segmentation

Report Scope

Report Attribute/Metric Details
Market Size 2023 11.2 (USD Billion)
Market Size 2024 12.34 (USD Billion)
Market Size 2032 16.7 (USD Billion)
Compound Annual Growth Rate (CAGR) 9.2 % (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke Pharma (US), Valent Pharmaceuticals(US)
  Key Market Opportunities Increasing cases of conditions like Crohn's disease, ulcerative colitis, and irritable bowel syndrome (IBS) drive demand for effective treatments.
  Key Market Drivers Increasing incidence of gastrointestinal diseases like GERD, IBS, and Crohn's disease.

FAQs

  1. INTRODUCTION
    1. DEFINITION
      1. RESEARCH OBJECTIVE
      2. ASSUMPTIONS & LIMITATIONS
    2. SCOPE OF STUDY
    3. LIMITATIONS
    4. MARKET STRUCTURE:
  2. RESEARCH METHODOLOGY
    1. RESEARCH PROCESS:
    2. PRIMARY RESEARCH
    3. SECONDARY RESEARCH:
  3. MARKET DYNAMICS
    1. DRIVERS
    2. RESTRAINTS
    3. OPPORTUNITIES
    4. MACROECONOMIC
    5. INDICATORS
  4. MARKET FACTOR ANALYSIS
    1. PORTERS FIVE FORCES MODEL
    2. BARGAINING POWER OF SUPPLIERS
    3. BARGAINING POWER OF BUYERS
    4. THREAT
    5. OF NEW ENTRANTS
    6. THREAT OF SUBSTITUTES
    7. INTENSITY OF RIVALRY
  5. AMERICAS GASTROINTESTINAL DRUG MARKET, BY DRUG CATEGORY
    1. ACID NEUTRALIZERS
    2. H2 ANATAGONISTS
    3. OTHERS
    4. ANTINFLAMMATORY
    5. OTHER
  6. ANTACID
  7. PROTON PUMP INHIBITORS
    1. LAXATIVES & ANTIDIARRHEAL
    2. ANTIEMETIC
  8. AMERICAS GASTROINTESTINAL DRUG MARKET, BY
    1. ROUTE OF ADMINISTRATION
    2. ORAL
    3. PARENTAL
    4. RECTAL
  9. AMERICAS GASTROINTESTINAL
  10. DRUG MARKET, BY DISEASES TYPE
    1. GASTROESPHAGEAL REFLUX
    2. DISEASES
    3. INFLAMMATORY BOWEL DISEASES
      1. ULCERTAVIE COLITIS
    4. CHRON’S DISEASE
    5. OTHER.
  11. AMERICAS GASTROINTESTINAL DRUG MARKET, BY
    1. END USERS
    2. HOSPITAL PHARMACIES
    3. RETAIL
    4. PHARMACIES
    5. OTHERS
  12. AMERICAS
  13. GASTROINTESTINAL DRUG MARKET, BY REGION
    1. INTRODUCTION
      1. NORTH AMERICA
    2. SOUTH AMERICA
  14. COMPETITIVE LANDSCAPE
    1. MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
    2. STRATEGIC PARTNERSHIP
    3. & ACQUISITION
  15. MERGER
  16. COMPANY PROFILE
    1. ABBVIE INC.
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. KEY DEVELOPMENTS
    2. FINANCIALS
    3. ABBOTT LABORATORIES
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. KEY DEVELOPMENTS
    4. FINANCIALS
    5. ALLERGEN PLC.
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. STRATEGY
    6. FINANCIALS
    7. KEY DEVELOPMENT
    8. BAYER AG
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    9. BOEHRINGER INGELHEIM GMBH
      1. PRODUCT OVERVIEW
      2. FINANCIALS
    10. OVERVIEW
    11. KEY DEVELOPMENTS
    12. GALXOSMITHKLINE
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
    13. KEY DEVELOPMENTS
    14. JASSEN PHARMACEUTICALS INC
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
    15. KEY DEVELOPMENTS
  17. 8 OTHERS

Americas Gastrointestinal Drugs Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions